Morgan Stanley initiated coverage of Cidara Therapeutics (CDTX) with an Overweight rating and $190 price target The company’s CD388 demonstrated meaningful flu prevention in a Phase 2 trial and is well positioned as a complement to vaccines, the analyst tells investors in a research note. The firm says that with Phase 3 interim data expected in June of 2026, it sees “broad protection and season-long durability as key differentiator” for the drug.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Cidara Therapeutics initiated with an Overweight at JPMorgan
- Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
- Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright